399 related articles for article (PubMed ID: 16979814)
1. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
2. Does testosterone have a role in erectile function?
Mikhail N
Am J Med; 2006 May; 119(5):373-82. PubMed ID: 16651047
[TBL] [Abstract][Full Text] [Related]
3. New achievement and novel therapeutic applications of PDE5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(3 Suppl):45-50. PubMed ID: 16042360
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of testosterone in the treatment of erectile dysfunction.
Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J
Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550
[TBL] [Abstract][Full Text] [Related]
5. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
De Young L; Yu D; Freeman D; Brock GB
Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
7. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
11. Vardenafil treatment for erectile dysfunction.
Crowe SM; Streetman DS
Ann Pharmacother; 2004 Jan; 38(1):77-85. PubMed ID: 14742800
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy and erectile dysfunction: the current status.
Lau DH; Kommu SS; Siddiqui EJ; Thompson CS; Morgan RJ; Mikhailidis DP; Mumtaz FH
Asian J Androl; 2007 Jan; 9(1):8-15. PubMed ID: 16888683
[TBL] [Abstract][Full Text] [Related]
13. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
Dunn ME; Althof SE; Perelman MA
Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
Berner MM; Kriston L; Harms A
Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
[TBL] [Abstract][Full Text] [Related]
16. The relationship between hypogonadism and erectile dysfunction.
Hwang TI; Lin YC
Int J Impot Res; 2008; 20(3):231-5. PubMed ID: 18305486
[TBL] [Abstract][Full Text] [Related]
17. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
Mehrotra N; Gupta M; Kovar A; Meibohm B
Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
[TBL] [Abstract][Full Text] [Related]
18. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
Eardley I
Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
[No Abstract] [Full Text] [Related]
19. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
Manganiello V
Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
[No Abstract] [Full Text] [Related]
20. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
Mulhall JP; Montorsi F
Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
